IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v119y2015i5p563-568.html
   My bibliography  Save this article

Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment

Author

Listed:
  • Petrou, Panagiotis
  • Vandoros, Sotiris

Abstract

The pharmaceutical market in Cyprus has been characterised by high volume and a steep increase in per-capita expenditure over the past decade. Most importantly, the market is fragmented due to the absence of universal health insurance, and the uninsured have to rely exclusively on the private market. The objective of this study is to examine the weaknesses of the Cypriot pharmaceutical market before the financial crisis; to discuss the measures recently introduced after recommendations by the Troika; and to propose interventions that can improve access to pharmaceuticals and efficiency without compromising health outcomes. Apart from the introduction of new pharmaceutical policies, we also recommend the swift implementation of universal health insurance.

Suggested Citation

  • Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    • Handle: RePEc:eee:hepoli:v:119:y:2015:i:5:p:563-568
    DOI: 10.1016/j.healthpol.2015.03.004
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851015000718
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2015.03.004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Tom Stargardt, 2011. "Modelling pharmaceutical price changes in Germany: a function of competition and regulation," Applied Economics, Taylor & Francis Journals, vol. 43(29), pages 4515-4526.
    2. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.
    3. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    4. Kanavos, Panos G. & Vandoros, Sotiris, 2011. "Determinants of branded prescription medicine prices in OECD countries," Health Economics, Policy and Law, Cambridge University Press, vol. 6(3), pages 337-367, July.
    5. Quaglio, GianLuca & Karapiperis, Theodoros & Van Woensel, Lieve & Arnold, Elleke & McDaid, David, 2013. "Austerity and health in Europe," Health Policy, Elsevier, vol. 113(1), pages 13-19.
    6. Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
    7. Cylus, Jonathan & Papanicolas, Irene & Constantinou, Elisavet & Theodorou, Mamas, 2013. "Moving forward: Lessons for Cyprus as it implements its health insurance scheme," Health Policy, Elsevier, vol. 110(1), pages 1-5.
    8. Maria Andreou & Panos Pashardes & Nicoletta Pashourtidou, 2010. "Cost and Value of Health Care in Cyprus," Cyprus Economic Policy Review, University of Cyprus, Economics Research Centre, vol. 4(1), pages 3-24, June.
    9. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
    10. Panos Kanavos & Joan Costa-Font & Elizabeth Seeley, 2008. "Competition in off-patent drug markets: Issues, regulation and evidence [‘Substitution laws, insurance coverage, and generic drug use’]," Economic Policy, CEPR, CESifo, Sciences Po;CES;MSH, vol. 23(55), pages 500-544.
    11. Hessel, Philipp & Vandoros, Sotiris & Avendano, Mauricio, 2014. "The differential impact of the financial crisis on health in Ireland and Greece: a quasi-experimental approach," LSE Research Online Documents on Economics 59610, London School of Economics and Political Science, LSE Library.
    12. Gené-Badia, Joan & Gallo, Pedro & Hernández-Quevedo, Cristina & García-Armesto, Sandra, 2012. "Spanish health care cuts: Penny wise and pound foolish?," Health Policy, Elsevier, vol. 106(1), pages 23-28.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Petrou, Panagiotis & Vandoros, Sotiris, 2018. "Healthcare reforms in Cyprus 2013–2017: Does the crisis mark the end of the healthcare sector as we know it?," Health Policy, Elsevier, vol. 122(2), pages 75-80.
    2. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    3. Lars Carlsen & Rainer Bruggemann, 2017. "Fragile State Index: Trends and Developments. A Partial Order Data Analysis," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 133(1), pages 1-14, August.
    4. Petrou, Panagiotis, 2021. "The 2019 introduction of the new National Healthcare System in Cyprus," Health Policy, Elsevier, vol. 125(3), pages 284-289.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    2. Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
    3. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.
    4. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
    5. Petrou, Panagiotis, 2021. "The 2019 introduction of the new National Healthcare System in Cyprus," Health Policy, Elsevier, vol. 125(3), pages 284-289.
    6. Tavares, Lara Patrício & Zantomio, Francesca, 2017. "Inequity in healthcare use among older people after 2008: The case of southern European countries," Health Policy, Elsevier, vol. 121(10), pages 1063-1071.
    7. Greta Falavigna & Roberto Ippoliti & Marinella Bertolotti & Franca Riva & Antonio Maconi, 2017. "Supportare la ricerca e l’innovazione in sanità tramite i modelli organizzativi: il caso dell’Azienda Ospedaliera “SS. Antonio e Biagio e Cesare Arrigo” di Alessandria/Supporting research and innovati," IRCrES Working Paper 201709, CNR-IRCrES Research Institute on Sustainable Economic Growth - Moncalieri (TO) ITALY - former Institute for Economic Research on Firms and Growth - Torino (TO) ITALY.
    8. Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.
    9. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    10. Herr, A. & Suppliet, M., 2011. "Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 11/18, HEDG, c/o Department of Economics, University of York.
    11. Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
    12. Michael Mueller & Alexander Frenzel, 2015. "Competitive pricing within pharmaceutical classes: evidence on “follow-on” drugs in Germany 1993–2008," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 73-82, January.
    13. Dominik J. Wettstein & Stefan Boes, 2019. "Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 143-162, April.
    14. Casagranda, Ivo & Costantino, Giorgio & Falavigna, Greta & Furlan, Raffaello & Ippoliti, Roberto, 2016. "Artificial Neural Networks and risk stratification models in Emergency Departments: The policy maker's perspective," Health Policy, Elsevier, vol. 120(1), pages 111-119.
    15. Isabel Aguilar-Palacio & Patricia Carrera-Lasfuentes & M. Rabanaque, 2015. "Youth unemployment and economic recession in Spain: influence on health and lifestyles in young people (16–24 years old)," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 60(4), pages 427-435, May.
    16. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    17. Paula K. Lorgelly & Amanda Adler, 2020. "Impact of a Global Pandemic on Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 339-343, June.
    18. Cristina Borra & Jerònia Pons-Pons & Margarita Vilar-Rodríguez, 2020. "Austerity, healthcare provision, and health outcomes in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 409-423, April.
    19. Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
    20. Tapia Granados, José A. & Rodriguez, Javier M., 2015. "Health, economic crisis, and austerity: A comparison of Greece, Finland and Iceland," Health Policy, Elsevier, vol. 119(7), pages 941-953.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:119:y:2015:i:5:p:563-568. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.